North Carolina Gov. Josh Stein has shown he has a different approach to being governor than his predecessor, former Democratic Gov. Roy Cooper, when it comes to working with Republicans.

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment ...

David Horowitz, the conservative author and activist, died on Tuesday at the age of 86, as confirmed by the David Horowitz Freedom Center, the think tank he established. The center announced on X ...

David Horowitz, a conservative commentator, author and activist, died on Tuesday at the age of 86, according to the David Horowitz Freedom Center, the conservative think tank he founded.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has a robust pipeline with approximately 45 product candidates in clinical development, including four regulatory approvals and nine regulatory ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat.

By Trip Gabriel David Horowitz, a radical leftist of the 1960s who did a political about-face to become an outspoken conservative author and activist, writing that Barack Obama had “betrayed ...

On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82. The company reported ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

Regeneron faced mixed results in Q1 2025 with challenges in its retinal franchise offset by strong pipeline progress and Dupixent’s robust performance. The company remains focused on resolving ...